SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

09 Feb 2023 Evaluate
The company's total revenue for the quarter ended December 2022 saw a slight change in the total revenue, having registered a total revenue of Rs. 28611.10 millions.A radical decline of -92.38% was reported in the net profit of the company for the quarter ended December 2022 to Rs. 404.00  millions from Rs. 5304.40 millions.Operating Profit reported a sharp decline to 2322.30 millions from 2437.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 28611.10 27319.90 4.73 84225.60 89162.80 -5.54 117716.70 110559.30 6.47
Other Income 171.00 354.70 -51.79 1177.80 1618.30 -27.22 2169.90 1290.90 68.09
PBIDT 2322.30 2437.00 -4.71 8564.40 -910.20 -1040.94 4261.30 21731.50 -80.39
Interest 307.50 158.10 94.50 690.00 488.90 41.13 734.70 406.20 80.87
PBDT 2014.80 2278.90 -11.59 7874.40 -1399.10 -662.82 3526.60 21325.30 -83.46
Depreciation 1340.30 1279.10 4.78 4021.40 3831.70 4.95 5141.90 5028.30 2.26
PBT 674.50 999.80 -32.54 3853.00 -5230.80 -173.66 -1615.30 16297.00 -109.91
TAX 270.50 -4304.60 -106.28 791.00 -3702.70 -121.36 271.70 3710.80 -92.68
Deferred Tax 142.90 -5455.40 -102.62 86.30 -3725.70 -102.32 -306.30 82.30 -472.17
PAT 404.00 5304.40 -92.38 3062.00 -1528.10 -300.38 -1887.00 12586.20 -114.99
Equity 909.60 908.40 0.13 909.60 908.40 0.13 909.00 907.40 0.18
PBIDTM(%) 8.12 8.92 -9.01 10.17 -1.02 -1096.12 3.62 19.66 -81.58

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×